During the last years, studies incorporating AD biomarkers have shown that higher baseline levels of amyloid-β (Aβ) deposition, as measured by positron emission tomography (PET), and higher cerebrospinal fluid (CSF) levels of tau/Aβ42 ratio are associated with greater prospective body weight decline [15, 16], and a recent study has reported a negative correlation between BMI change and amyloid-PET burden [17]. Here, MAPT is linked to Alzheimer disease.